Objective:To know the clinical characteristics of liver injury related to levetiracetam (LEV).Methods:The relevant databases at home and abroad (up to August 31st, 2021) were searched and the case reports on LEV-associated liver injury were collected. Clinical information including patients′ basic characteristics, LEV application, concomitant medication, and occurrence, treatment, and outcome of liver injury, etc. were collected and analyzed by descriptive statistical method.Results:A total of 17 patients were enrolled in the study, including 9 males and 8 females, aged from 1 month to 76 years with an average age of 35 years. The primary disease was idiopathic epilepsy in 7 patients and secondary epilepsy in 10 patients. Five cases had comorbidities. Thirteen patients had drug dosage records, all of which were within the range recommended in the labels; 13 patients had concomitant medication. The time from LEV treatment to the occurrence of liver injury ranged from several hours to 5 months in 17 patients and it was ≤2 months in 14 patients. The classification of liver injury was hepatocellular type in 7 patients, cholestasis type in 1 patient, mixed type in 1 patient, and unable to be determined due to lack of relevant data in 8 patients. Clinical symptoms were recorded in 10 patients, including yellowish skin and sclera in 5 cases, fever in 4 cases, nausea in 2 cases, vomiting in 2 cases, and biliuria in 2 cases. LEV was discontinued in 14 patients, 4 of whom did not received other interventions and the liver function was improved or returned to normal 2 to 20 days after drug withdrawal; LEV was replaced with other antiepileptic drugs and/or symptomatic treatments in 10 patients, 9 patients′ liver function were improved or returned to normal (the recovery time was 5-37 days in 5 patients and not recorded in 4 patients), 1 patient had normal liver function after liver transplantation, but the liver injury recurred after LEV use again and was improved after drug withdrawal. Two patients did not stop LEV, one underwent liver transplantation due to liver failure and hepatic encephalopathy, and the prognosis was unknown; the other one developed fulminant liver failure and died. One patient had no record of whether or not stopping LEV, and the liver function returned to normal after artificial liver support treatment.Conclusions:LEV-related liver injury mostly occurred within 2 months after drug administration. The clinical manifestations were similar to the liver injury caused by other drugs. Liver function usually was improved or returned to normal after the drug withdrawal. The patients who did not stop LEV had poor prognosis, and severe cases could lead to liver failure or death.

Objective:To know the clinical characteristics of liver injury related to levetiracetam (LEV).Methods:The relevant databases at home and abroad (up to August 31st, 2021) were searched and the case reports on LEV-associated liver injury were collected. Clinical information including patients′ basic characteristics, LEV application, concomitant medication, and occurrence, treatment, and outcome of liver injury, etc. were collected and analyzed by descriptive statistical method.Results:A total of 17 patients were enrolled in the study, including 9 males and 8 females, aged from 1 month to 76 years with an average age of 35 years. The primary disease was idiopathic epilepsy in 7 patients and secondary epilepsy in 10 patients. Five cases had comorbidities. Thirteen patients had drug dosage records, all of which were within the range recommended in the labels; 13 patients had concomitant medication. The time from LEV treatment to the occurrence of liver injury ranged from several hours to 5 months in 17 patients and it was ≤2 months in 14 patients. The classification of liver injury was hepatocellular type in 7 patients, cholestasis type in 1 patient, mixed type in 1 patient, and unable to be determined due to lack of relevant data in 8 patients. Clinical symptoms were recorded in 10 patients, including yellowish skin and sclera in 5 cases, fever in 4 cases, nausea in 2 cases, vomiting in 2 cases, and biliuria in 2 cases. LEV was discontinued in 14 patients, 4 of whom did not received other interventions and the liver function was improved or returned to normal 2 to 20 days after drug withdrawal; LEV was replaced with other antiepileptic drugs and/or symptomatic treatments in 10 patients, 9 patients′ liver function were improved or returned to normal (the recovery time was 5-37 days in 5 patients and not recorded in 4 patients), 1 patient had normal liver function after liver transplantation, but the liver injury recurred after LEV use again and was improved after drug withdrawal. Two patients did not stop LEV, one underwent liver transplantation due to liver failure and hepatic encephalopathy, and the prognosis was unknown; the other one developed fulminant liver failure and died. One patient had no record of whether or not stopping LEV, and the liver function returned to normal after artificial liver support treatment.Conclusions:LEV-related liver injury mostly occurred within 2 months after drug administration. The clinical manifestations were similar to the liver injury caused by other drugs. Liver function usually was improved or returned to normal after the drug withdrawal. The patients who did not stop LEV had poor prognosis, and severe cases could lead to liver failure or death.

Objective: To study the effect of oral metformin on the prognosis of patients with gastric cancer. Methods: The clinical data of 364 patients with gastric cancer admitted to the First Affiliated Hospital of Medical College of Shantou University from January 2013 to December 2017 were collected.The patients were divided into metformin group (31 cases), non-metformin group (35 cases) and non-diabetic group (298 cases) according to whether they were diabetes or treated with metformin.The mortality and survival of the three groups were compared. Results: The mortality rate was 12.9%(4/31) in the metformin group, 74.3%(26/35) in the non-metformin group, 52.0%(155/298) in the non-diabetic group, and the mortality rate in the metformin group was lower than that in the other two groups, the differences were statistically significant(χ²=10.081, P=0.001; χ²=7.681, P=0.006), and the metformin group had the lowest mortality rate.There was no statistically significant difference between the non-metformin group and the non-diabetic group (χ²=1.665, P=0.197). The survival time of the metformin group, non-metformin group and non-diabetic group were (29.017±16.254) months, (9.692±10.355) months and (16.748±8.526)months, respectively.The survival time of the metformin group was longer than that of the non-metformin group (t=5.827, P=0.000) and the non-diabetic group (t=6.843, P=0.000), and the survival time of the non-diabetic group was longer than that of the non-metformin group (t=4.523, P=0.000), and the overall survival of patients in the metformin group was prolonged.Clinical staging, treatment of gastric cancer, alcohol consumption and oral metformin treatment were independent factors influencing the prognosis of patients with gastric cancer. Conclusion Oral metformin can improve the prognosis of patients with gastric cancer and prolong the life of patients.

OBJECTIVE:To promote the application of single-disease entity quality control in children with community acquired pneumonia.METHODS:According to the requirements of "Single-disease Entity Quality Control Index" issued by Ministry of Public Health,280 children with community acquired pneumonia in our hospital were analyzed retrospectively in respect of admission standard,pathogen inspection,selection of antibiotics,medication time,treatment course,health education,clinical efficacy and cost of hospitalization.RESULTS & CONCLUSION:The diagnosis and treatment of children community acquired pneumonia in our hospital are in line with "Single-disease Entity of Pneumonia Quality Control Index" while detection rate of bacterial cultivation and the level of sensitivity test should be improved.

OBJECTIVETo learn the epidemiologic characteristics of rotavirus diarrhea in three hospitals under sentinel surveillance from August 2001 to July 2004 and to provide background information for developing and implementing rotavirus vaccine.

METHODSData from hospital-based rotavirus surveillance among children < 5 years old hospitalized with acute diarrhea was used. Patients' clinic information and feces specimens were collected. Specimens were tested and typed for rotavirus.

RESULTSTotally, 3121 specimens were tested and the detection rate of rotavirus was 51%. Among all the children with rotavirus diarrhea, 94% were < 2 years old. G3 (69.9%) was the most prevalent serotype followed by G1 (6.6%) and G2 (2.9%). P[8] was the most common genotype of rotavirus. The most common G-P combination identified in this study was P[8] G3 (64.0%). Seveal other combinations of minor frequency were also identified.

CONCLUSIONRotavirus infection was most commonly seen among children < 5 years old hospitalized with acute diarrhea in the three hospitals. It is important to develop and implement rotavirus vaccine to prevent and control severe rotavirus infection. Because of the diversity of rotavirus strains, it is necessary to perform rotavirus strain surveillance to understand the dynamic nature of viral transmission.

Child, Preschool ; China ; epidemiology ; Diarrhea ; epidemiology ; virology ; Feces ; virology ; Female ; Hospitals ; statistics & numerical data ; Humans ; Infant ; Infant, Newborn ; Male ; Rotavirus Infections ; epidemiology ; virology ; Sentinel Surveillance